FISH Diagnostic Assessment of MDM2 Amplification in Liposarcoma: Potential Pitfalls and Troubleshooting Recommendations

Int J Mol Sci. 2023 Jan 10;24(2):1342. doi: 10.3390/ijms24021342.

Abstract

MDM2 amplification represents the leading oncogenic pathway and diagnostic hallmark of liposarcoma, whose assessment is based on Fluorescence In Situ Hybridization (FISH) analysis. Despite its diagnostic relevance, no univocal interpretation criteria regarding FISH assessments of MDM2 amplification have been established so far, leading to several different approaches and potential diagnostic misinterpretations. This study aims to address the most common issues and proposes troubleshooting guidelines for MDM2 amplification assessments by FISH. We retrospectively retrieved 51 liposarcomas, 25 Lipomas, 5 Spindle Cell Lipoma/Pleomorphic Lipomas, and 2 Atypical Spindle Cell Lipomatous Tumors and the corresponding MDM2 FISH analysis. We observed MDM2 amplification in liposarcomas cases only (43 out of 51 cases) and identified three MDM2-amplified patterns (scattered (50% of cases), clustered (14% of cases), and mixed (36% of cases)) and two nonamplified patterns (low number of signals (82% of cases) and polysomic (18% of cases)). Based on these data and published evidence in the literature, we propose a set of criteria to guide MDM2 amplification analysis in liposarcoma. Kindled by the compelling importance of MDM2 assessments to improve diagnostic and therapeutic liposarcoma management, these suggestions could represent the first step to develop a univocal interpretation model and consensus guidelines.

Keywords: FISH; MDM2 amplification; MDM2 interpretation guidelines; liposarcoma.

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Gene Amplification
  • Humans
  • In Situ Hybridization, Fluorescence
  • Lipoma*
  • Liposarcoma* / diagnosis
  • Liposarcoma* / genetics
  • Liposarcoma* / pathology
  • Proto-Oncogene Proteins c-mdm2 / genetics
  • Proto-Oncogene Proteins c-mdm2 / metabolism
  • Retrospective Studies

Substances

  • Proto-Oncogene Proteins c-mdm2
  • Biomarkers, Tumor
  • MDM2 protein, human

Grants and funding

This research received no external funding.